Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck and : Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 01:45pm CET

Release date- 02102017 - EAGAN, MN - Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera's novel phase 2 cancer immunotherapy.

These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors. The high profile late-breaking session of the AACR-NCI- EORTC will feature initial translational research from Biothera's ongoing phase 2 clinical study combining Imprime PGG and Merck's anti-PD-1 antibody, Keytruda, for the treatment of biomarker-positive patients with triple negative breast cancer or metastatic melanoma.

About Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.

Contact:

David Walsh

Tel: 651-256-4606

Email: [email protected]

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
11:36aMERCK AND : offers $502 million for promising Australian cancer cell-killing res..
AQ
11:19aBig pharma could turn to viruses to boost cancer immunotherapies
AQ
09:36aMERCK AND : Alethea Capital Management Has Cut By $656,512 Its Merck & Co (MRK) ..
AQ
09:26aMERCK AND : Mercks melanoma drug shows early promise for resistant cancers in Ph..
AQ
09:26aLEAP THERAPEUTICS : Reports Fourth Quarter and Full Year 2017 Financial Results ..
AQ
02/23MERCK AND : Ferring Pharmaceuticals and MSD Announce Completion of Largest Clini..
AQ
02/23ASTRAZENECA : Lynparza CHMP for ovarian cancer maintainance
AQ
02/23MERCK AND : LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-S..
BU
02/23MERCK AND : plans to boost its immunotherapy drugs with tumor-bursting viruses
AQ
02/23MERCK AND : buys cancer-killing virus firm Viralytics for $394m
AQ
More news
News from SeekingAlpha
08:00a3 THINGS IN BIOTECH YOU SHOULD LEARN : February 23, 2018 
02/23Arcus Biosciences Files To Raise $100 Million In IPO 
02/23European advisory group backs the use of Merck's Isentress for newborns 
02/23European advisory group backs expanded use for AstraZeneca's Lynparza 
02/22ACETO : Collapsing Generic Drug Pricing Brings Risk Of Covenant Violations 
Financials ($)
Sales 2018 41 703 M
EBIT 2018 13 718 M
Net income 2018 8 465 M
Debt 2018 13 842 M
Yield 2018 3,52%
P/E ratio 2018 16,80
P/E ratio 2019 13,51
EV / Sales 2018 3,90x
EV / Sales 2019 3,75x
Capitalization 149 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,2 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-3.02%148 618
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
AMGEN4.92%132 428